Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma

Dec 15 2008

• By Cathy Dombrowski

Related Content

FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs

Dec 03 2007

Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential

Mar 03 2006

AstraZeneca Submits Symbicort For Asthmatics As Young As Six

Jun 04 2008

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window